Activation of the MET oncogenic pathway has been implicated in the development of aggressive cancers that are difficult to treat with current chemotherapies. This has led to an increased interest in developing novel therapies that target the MET pathway. However, most existing drug modalities are confounded by their inability to specifically target and/or antagonize this pathway. Anticalins, a novel class of monovalent small biologics, are hypothesized to be "fit for purpose" for developing highly specific and potent antagonists of cancer pathways. Here, we describe a monovalent full MET antagonist, PRS-110, displaying efficacy in both ligand-dependent and ligand-independent cancer models. PRS-110 specifically binds to MET with high affinity and blocks hepatocyte growth factor (HGF) interaction. Phosphorylation assays show that PRS-110 efficiently inhibits HGF-mediated signaling of MET receptor and has no agonistic activity. Confocal microscopy shows that PRS-110 results in the trafficking of MET to late endosomal/lysosomal compartments in the absence of HGF. In vivo administration of PRS-110 resulted in significant, dose-dependent tumor growth inhibition in ligand-dependent (U87-MG) and ligand-independent (Caki-1) xenograft models. Analysis of MET protein levels on xenograft biopsy samples show a significant reduction in total MET following therapy with PRS-110 supporting its ligand-independent mechanism of action. Taken together, these data indicate that the MET inhibitor PRS-110 has potentially broad anticancer activity that warrants evaluation in patients.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. / Olwill SA;Joffroy C;Gille H;Vigna E;Matschiner G;Allersdorfer A;Lunde BM;Jaworski J;Burrows JF;Chiriaco C;Christian HJ;Hülsmeyer M;Trentmann S;Jensen K;Hohlbaum AM;Audoly L. - In: MOLECULAR CANCER THERAPEUTICS. - ISSN 1535-7163. - ELETTRONICO. - 12:11(2013), pp. 2459-2471.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

VIGNA, Elisa;
2013

Abstract

Activation of the MET oncogenic pathway has been implicated in the development of aggressive cancers that are difficult to treat with current chemotherapies. This has led to an increased interest in developing novel therapies that target the MET pathway. However, most existing drug modalities are confounded by their inability to specifically target and/or antagonize this pathway. Anticalins, a novel class of monovalent small biologics, are hypothesized to be "fit for purpose" for developing highly specific and potent antagonists of cancer pathways. Here, we describe a monovalent full MET antagonist, PRS-110, displaying efficacy in both ligand-dependent and ligand-independent cancer models. PRS-110 specifically binds to MET with high affinity and blocks hepatocyte growth factor (HGF) interaction. Phosphorylation assays show that PRS-110 efficiently inhibits HGF-mediated signaling of MET receptor and has no agonistic activity. Confocal microscopy shows that PRS-110 results in the trafficking of MET to late endosomal/lysosomal compartments in the absence of HGF. In vivo administration of PRS-110 resulted in significant, dose-dependent tumor growth inhibition in ligand-dependent (U87-MG) and ligand-independent (Caki-1) xenograft models. Analysis of MET protein levels on xenograft biopsy samples show a significant reduction in total MET following therapy with PRS-110 supporting its ligand-independent mechanism of action. Taken together, these data indicate that the MET inhibitor PRS-110 has potentially broad anticancer activity that warrants evaluation in patients.
12
11
2459
2471
http://mct.aacrjournals.org/content/12/11/2459.long
Olwill SA;Joffroy C;Gille H;Vigna E;Matschiner G;Allersdorfer A;Lunde BM;Jaworski J;Burrows JF;Chiriaco C;Christian HJ;Hülsmeyer M;Trentmann S;Jensen K;Hohlbaum AM;Audoly L
File in questo prodotto:
File Dimensione Formato  
Olwill Vigna Mol Canc Ther 2013.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/157923
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact